TABLE OF CONTENTS

Introduction ................................................. 4
Organization Overview ........................................ 6
Membership .................................................. 10
Lung Cancer Awareness Month .......................... 12
Communications ............................................. 14
Publications .................................................. 16
Meetings ...................................................... 20
Educational Activities ....................................... 26
Task Force and Committee Initiatives ................. 30
Awards ......................................................... 34
IASLC Foundation ........................................... 46
INTRODUCTION
AND WELCOME

Dear Friends:

It has certainly been a noteworthy year with many rewarding moments. Thanks to the IASLC staff, board of directors and our members throughout the world for their hard work, dedication and steadfast commitment to the organization’s mission to conquer thoracic cancers worldwide.

Over the course of its 42-year history, the IASLC has promoted research into all aspects of lung cancer and other thoracic malignancies. These determined and quite often groundbreaking efforts have greatly influenced and impacted the diagnoses, treatment, management and prevention of thoracic cancers globally.

Lung cancer remains a worldwide health problem and accounts for 19 percent of all cancer deaths. Globally, 1.8 million people are diagnosed each year; 1.6 million will die. But, despite the low survival rate, there are many reasons to be optimistic in 2017.

We recognize that it takes a concerted and highly-organized international effort to rid the world of the burden of lung cancer and we are encouraged by developments in immunotherapy and molecular biology that have led to personalized treatment options. As a result, lung cancer research and treatment has gradually been transformed into a role model for modern cancer treatment.

Among the major highlights from the past year is the completion of the 8th Edition of the Tumor, Node and Metastasis Classification for Lung Cancer, Thymic Tumors and Mesothelioma. Staging is crucial for the treatment and management of lung cancer, and this updated classification represents a data-driven approach that includes several innovations that will likely lead to changes in clinical practice. In the latest edition, tumor size is now a much more relevant prognostic factor, and small changes in size mean important changes in prognosis. These key modifications were informed by analysis of data from nearly 71,000 patients with non-small cell lung cancer and more than 6,100 with small cell lung cancer.

Continuing its commitment of educating and encouraging the next generation of researchers, the IASLC Foundation endowed 11 individuals from all corners of the globe with fellowships and scholarships to support their innovative efforts.

Another key area of emphasis for the IASLC in 2016 was our work in lung cancer awareness and advocacy. November is recognized as Lung Cancer Awareness Month and, in the past, has been carried out by a number of different advocacy groups. Last year, the IASLC took the lead and brought together more than 20 organizations in the U.S. and Europe for a single, harmonized public awareness campaign complete with a new website, a common logo, colorful infographics, coordinated messaging and vibrant photos and inspiring videos demonstrating people living full lives despite having been affected by lung cancer. The results were overwhelming as evidenced by the tremendous amount of media recognition and social media chatter worldwide.

Plans are shaping up for the 2017 version of Lung Cancer Awareness Month to be even bigger and more impactful by extending the campaign to other parts of the world.

IASLC membership topped 5,500 in 2016—a 10 percent increase over the previous year and an impressive 45 percent increase from 2014. A conduit to both personal and professional development, an IASLC membership provides the road map for achievement for everyone on the entire multidisciplinary team – physicians, scientists, nurses, patient advocates, survivors and others. Members have the opportunity to be part of the global conversation that influences what happens next.

Continuing its commitment of educating and encouraging the next generation of researchers, the IASLC endowed 11 individuals from all corners of the globe with fellowships and scholarships to support their innovative efforts.
The IASLC Board of Directors also sponsored the Foundation Fellowship Matching Gift Challenge which encouraged giving from those already involved with the organization as well as from the public. Additionally, the Mozart’s Requiem Concert, held during the IASLC 17th World Conference on Lung Cancer in Vienna, Austria, bolstered awareness and support for the IASLC Foundation. All of these efforts amounted to a four-fold increase in the Foundation’s annual fund donor base – something we are very proud of!

IASLC meetings provide an exceptional opportunity for learning about the latest scientific advances and for sharing clinical experiences with colleagues. Our largest meeting of the year, the 17th World Conference on Lung Cancer, was a huge success. With more than 6,500 delegates from nearly 100 countries learning, networking and exchanging information, there is no doubt that many doors were opened for collaboration. Coming together and working together ultimately benefits our patients and greatly advances our cause.

In 2017 we continue to raise the bar in lung cancer education and awareness and we welcome the challenges it brings. There is a need for more initiatives to help doctors, patients and caregivers navigate the ever-changing cancer care landscape. We will continue the fight to change public perception and lessen the stigma of lung cancer. We’ll also work to get more patients into clinical trials by shrinking the knowledge gap between researchers and patients. It’s our responsibility to get the word out to patients about the importance of molecular testing and how it could allow them to take advantage of specific targeted treatment options.

Greater knowledge can result in patients taking a more active role in their care and affecting change in legislative or regulatory policies. And when that happens, everybody wins.

OUR KEY AREAS OF FOCUS FOR 2017:
› Reinforcing prevention efforts worldwide
› Influencing early detection/screening
› Encouraging greater doctor-patient communication regarding treatment options
› Furthering personalized, targeted treatment therapies via molecular testing
› Increasing the number of patients in clinical trials

The future is optimistic, but we can’t do it alone. We look forward to working with you in 2017. Together, we continue the fight and remain committed to reducing lung cancer mortality across the globe.

David P. Carbone, MD, PhD
President, IASLC

Fred R. Hirsch, MD, PhD
Chief Executive Officer, IASLC
ORGANIZATION OVERVIEW

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Since its inception in 1974, the IASLC has worked to promote research into all aspects of lung cancer and thoracic malignancies while encouraging worldwide cancer prevention efforts.

Bringing together medical doctors, scientists, nurses, health professionals, patients, industry partners, government officials and advocacy group members, the IASLC is united in the goal of prevention, screening, imaging, diagnosis and treatment of thoracic malignancies. Members collaborate throughout the world, sharing clinical and scientific experiences and expertise, while positioning the IASLC as the premier global source of timely, relevant and valued information. In addition, members actively contribute by leading IASLC meetings and conferences; playing active roles on committees; providing presentations on basic, cutting-edge, translational and clinical science; and engaging in robust dialogue and partnerships to further the IASLC mission.

Mission

- To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and thoracic malignancies
- To provide education and information about lung cancer and other thoracic malignancies to IASLC members, the medical community at large and the public
- To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world

Board of Directors – The IASLC Board of Directors is multidisciplinary and each member brings an abundance of clinical and scientific expertise along with a broad base of experience with other professional societies and familiarity with institutional leadership. IASLC board members promote ongoing growth in programs and new initiatives through their strategic guidance and operational and financial oversight.

Headquarters Staff – Under the leadership of the CEO, the IASLC staff implements a wide range of education, membership, communications, outreach, fundraising and scientific programs. From facilitating worldwide conferences to producing webinars, newsletters and digital applications, to collaborating with members and disseminating the latest scientific information to stakeholders throughout the world, the staff supports, gives expert advice and helps implement decisions made by IASLC committees and the board of directors. The staff is also responsible for the financial management of the IASLC’s operations and assets.
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer. Since its inception in 1974, the IASLC has worked to promote research into all aspects of lung cancer and thoracic malignancies. Bringing together medical doctors, scientists, nurses, health professionals, patients, industry partners, government officials and advocacy group members, the IASLC is united in the goal of prevention, screening, imaging, diagnosis and treatment of thoracic malignancies. Members collaborate throughout the world, sharing clinical and scientific experiences and expertise, while positioning the IASLC as the premier global source of timely, relevant and valued information. In addition, members actively contribute by leading IASLC meetings and conferences; playing active roles on committees; providing presentations on basic, cutting-edge, translational and clinical science; and engaging in robust dialogue and partnerships to further the IASLC mission.

**Mission**

› To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and thoracic malignancies
› To provide education and information about lung cancer and other thoracic malignancies to IASLC members, the medical community at large and the public
› To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world

**Board of Directors**

- **David P. Carbone**
  President
  USA, 2015-2017

- **Giorgio Scagliotti**
  President-Elect
  Italy, 2015-2017

- **Tony Mok**
  Past President
  Hong Kong, 2015-2017

- **Fred R. Hirsch**
  Chief Executive Officer
  USA

- **David Gandara**
  Treasurer
  USA, 2013-2017

- **Michael Boyer**
  Australia, 2015-2019

- **Laurie Gaspar**
  USA, 2015-2017

- **David Harpole**
  USA, 2015-2019

- **Norihiko Ikeda**
  Japan, 2015-2019

- **Pasi A. Janne**
  USA, 2015-2017

- **Keith Kerr**
  United Kingdom, 2015-2017

- **Francoise Mornex**
  France, 2015-2017

- **Yuichiro Ohe**
  Japan, 2013-2017

- **Solange Peters**
  Switzerland, 2013-2017

- **Robert Pirker**
  Austria, 2015-2019

- **Martin Reck**
  Germany, 2015-2019

- **Miyako Salouchi**
  Japan, 2015-2019

- **William D. Travis**
  USA, 2013-2017

- **Heather Wakelee**
  USA, 2015-2019

- **Yi-Long Wu**
  China, 2015-2017
IASLC STAFF

Fred R. Hirsch
Chief Executive Officer

Pia Hirsch
Senior Director of Education, Corporate Relations and Governance

Kristin Richeimer
Director of Membership

John Skadow
Director of Finance

Colleen Miller
Director of Communications

Murry Wynes
Director of Scientific Affairs

Mary Todd
Managing Editor, Journal of Thoracic Oncology

Debbie Clements
Conference Coordinator

Adam Mohrbacher
Content Specialist

Carlos Ferreira
Continuing Medical Education Compliance Specialist

Paul Silvey
Education Programs Coordinator

Karen Muth
Executive Assistant to the CEO

Michelle Gruver
Fellowship Coordinator

Kristin Schultz
Membership Coordinator

Michelle Martinez
Membership Data and Technical Analyst

Becky Bunn
Public Relations Manager

Jacinta Wiens
Scientific Affairs Project Manager

Vengie Lau
Support, Asia Office
IASLC COUNCIL OF REGENTS

The IASLC Council of Regents, founded in 2011 and appointed the IASLC Board of Directors is a worldwide network of IASLC members responsible for ensuring effective communication between the association and its members in a particular country or geographic area. Regents meet annually at the IASLC World Conference on Lung Cancer and work with the IASLC membership team throughout the year to assist in recruiting new members, provide translations and content for IASLC publications, initiate or support educational programs and identify opportunities for growth in their region.

2016 COUNCIL OF REGENTS

<table>
<thead>
<tr>
<th>REGENT AREA</th>
<th>REGENT NAME</th>
<th>SPECIALITY &amp; LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australasia</td>
<td>Nick Pavlakis</td>
<td>Medical Oncology, Sydney, Australia</td>
</tr>
<tr>
<td>Central America and Mexico</td>
<td>Oscar Arrieta</td>
<td>Medical Oncology, Mexico City, Mexico</td>
</tr>
<tr>
<td>Central America and Mexico</td>
<td>Jaime de la Garza</td>
<td>Medical Oncology, Mexico City, Mexico</td>
</tr>
<tr>
<td>Central Europe</td>
<td>Gyula Ostoros</td>
<td>Medical Oncology, Budapest, Hungary</td>
</tr>
<tr>
<td>China</td>
<td>Yi-Long Wu</td>
<td>Thoracic Surgery, Guangzhou</td>
</tr>
<tr>
<td>Europe</td>
<td>Paul de Leyn</td>
<td>Thoracic Surgery, Leuven, Belgium</td>
</tr>
<tr>
<td>Europe</td>
<td>Ioannis Gkiozos</td>
<td>Pulmonology, Athens, Greece</td>
</tr>
<tr>
<td>Gulf States and Arabia</td>
<td>Khaled Al-Kattan</td>
<td>Thoracic Surgery, Riyadh, Saudi Arabia</td>
</tr>
<tr>
<td>Indian Subcontinent</td>
<td>Navneet Singh</td>
<td>Pulmonology, Chandigarh</td>
</tr>
<tr>
<td>Japan</td>
<td>Shuji Sakai</td>
<td>Thoracic Surgery, Tokyo</td>
</tr>
<tr>
<td>North America</td>
<td>Brian Lally</td>
<td>Radiation Oncology, Miami, Florida, USA</td>
</tr>
<tr>
<td>North America</td>
<td>Charles A. Powell</td>
<td>Pulmonology, New York, New York, USA</td>
</tr>
<tr>
<td>North America</td>
<td>Gerard A. Silvestri</td>
<td>Pulmonology, Charleston, South Carolina, USA</td>
</tr>
<tr>
<td>South America</td>
<td>Eduardo Richardet</td>
<td>Medical Oncology, Cordoba, Argentina</td>
</tr>
<tr>
<td>South Korea</td>
<td>Young Tae Kim</td>
<td>Thoracic Surgery, Seoul</td>
</tr>
<tr>
<td>Southeast Asia</td>
<td>Ibrahim Wahid</td>
<td>Radiation Oncology, Kuala Lumpur, Malaysia</td>
</tr>
<tr>
<td>Southern Africa</td>
<td>Anthony Linegar</td>
<td>Thoracic Surgery, Cape Town, South Africa</td>
</tr>
<tr>
<td>Russia</td>
<td>Valeriy Breder</td>
<td>Medical Oncology, Moscow</td>
</tr>
<tr>
<td>Taiwan</td>
<td>James Chih-Hsin Yang</td>
<td>Medical Oncology, Taipei</td>
</tr>
<tr>
<td>Turkey</td>
<td>Deniz Yalman</td>
<td>Radiation Oncology, Izmir</td>
</tr>
<tr>
<td>United Kingdom and Ireland</td>
<td>Richard Booton</td>
<td>Pulmonology, Manchester, England</td>
</tr>
</tbody>
</table>
MEMBERSHIP

IASLC membership topped the 5,500 mark in 2016 for the first time in its 42-year history. Open to the entire multidisciplinary spectrum of lung cancer researchers and patient providers, IASLC member physicians, scientists, nurses, patient advocates, survivors and others join a global network united in the common goal of eradicating thoracic malignancies.

Working together, IASLC members have the opportunity to forge connections with one another and collaborate across the globe to directly influence future developments in lung cancer— from public education, screening and diagnosis, to patient treatment and support. Our members gain access to the latest groundbreaking research as well as educational opportunities to help them keep pace with the rapidly changing lung cancer landscape and then apply that forward-thinking knowledge to their patients and practices worldwide.

By offering professional and personal development opportunities, the IASLC provides its membership base with pathways to advance and grow in their professions and areas of interest. Likewise, extensive networking, mentoring and leadership opportunities set the association apart by delivering tremendous value to members in all disciplines.

In 2016, the IASLC experienced a 10 percent increase over the previous year by actively engaging current members and by creating new and innovative ways of reaching new members.

Several key initiatives are credited for this continued growth:

IASLC 17th World Conference on Lung Cancer (WCLC): The conference registration process was improved and data sharing initiatives made it possible to capture new members as individuals completed WCLC conference registration. Additionally, many new members took advantage of the multi-year discount offered on site at the WCLC 2016 in Vienna.

Partner Society Offers: The enrollment of members of several thoracic-related groups and societies through targeted promotions resulted in new members, including the full membership of the Polish Lung Cancer Group and the Hungarian Lung Cancer Society.

Membership Booth Promotions: The IASLC had a membership booth presence at a European radiation oncology conference and at the WCLC 2016, where new members were enrolled on site, and existing members received member recognition items (exclusive member pin and tote bag) while learning about the latest IASLC activities and newest member benefits.

Early Career and Survivor Members: The increased promotion of complimentary fellow and survivor memberships led to significant growth in this category. Early career physicians and investigators can also benefit from this membership while eventually evolving into paying members.

Improved Technology: Key enhancements to the member database and an improved email marketing platform provided better quality data and enabled more frequent notices to be distributed to lapsed members.

ATTRACTING MEMBERS FROM THE MULTIDISCIPLINARY TEAM

Several years ago, the IASLC established a goal of educating the entire multidisciplinary team of lung cancer providers. To accomplish that goal, the IASLC updated its membership communications to reflect this inclusive effort and sought to increase its membership among pathologists, diagnostic radiologists, nurses and allied health professionals, community practitioners and industry professionals. This endeavor continues today.
**Membership Benefits**

- Member access to the Journal of Thoracic Oncology – the world’s premier lung cancer journal
- Member discount to the IASLC World Conference on Lung Cancer (WCLC) and all other IASLC meetings
- Collaboration with thoracic oncology experts worldwide
- Online education discounts, free Continuing Medical Education (CME) and complimentary webinars
- Member discount to WCLC virtual meetings (online library of presentations)
- IASLC membership card mailed annually
- Monthly newsletter and updates on key events, grants and other opportunities for members
- Member listing and access to the IASLC member directory
- Eligibility to serve on the IASLC Board of Directors and member committees
- Eligibility for fellowship and travel awards
- Eligibility to vote for the IASLC Board of Directors

**Looking Ahead**

In 2017, the IASLC has aggressive goals for increasing its membership base and for improving the experience of both new and returning members. The IASLC Membership Committee and staff are undertaking a comprehensive, strategic review of the membership program to develop a plan for sustainable membership growth and expansion of benefits and quality of service, with the ultimate goal of successfully meeting the complex needs of the worldwide community of thoracic oncology stakeholders.

The IASLC plans to improve the communications process for new members to help them stay up-to-date with information most relevant to their specialty and region. Software upgrades and an updated member portal will be introduced in 2017. Additionally, the organization will engage more members at conferences around the world, particularly among the under-represented subspecialties such as radiation oncology, thoracic surgery, pulmonology, pathology, nursing and allied health.

Expanding the geographic reach of the IASLC’s membership base is also on tap for 2017. With the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan, a surge in membership from Asia is expected.
What began as a single day of recognition in 1995, Lung Cancer Awareness Month, recognized each November, has grown into a month-long, harmonized, worldwide initiative designed to bring the spotlight to the cancer that leads to the most deaths across the globe each year. And, although everyone involved is steadfastly focused on prevention, the IASLC and its partners in Lung Cancer Awareness Month also strive to turn lung cancer from a deadly disease into a chronically managed one. Lung Cancer Awareness Month celebrates survivors, shares the tremendous progress being made and offers hope to all affected.

Throughout the month of November, survivors, caregivers, nurses, health professionals, researchers and advocates shared stories about how they’ve been personally impacted by lung cancer. The 2016 campaign saw many different organizations coming together, from research to advocacy, complete with a common logo, colorful infographics, coordinated messaging, vibrant photos and inspiring videos.

**The public awareness campaign included:**

- More than 60 survivors and caregivers sharing their stories on the website – www.LCAM.org
- More than 20 partner organizations spreading the word
- More than 25,000 pins, bracelets, T-shirts and posters distributed during November
- LCAM.org receiving more than 30,000 unique visits
- LCAM Facebook page garnering more than 39,000 likes
- LCAM Twitter account featuring daily tweets of survivor stories
- LCAM Twitter hashtag – #LCAM – used by the global lung cancer community
- LCAM YouTube Channel’s 15 videos receiving over 2,000 views
- Print ad campaign with ads in The New York Times and The Wall Street Journal
- Digital ad campaign utilizing Facebook, Twitter and Google resulting in eight times the industry benchmark for the number of click-throughs
- Kickoff press conference at the National Press Club in Washington, D.C.

An even bigger initiative is planned for 2017, with a kickoff event taking place in late February. The concerted public awareness campaign will focus on scientific advances linked with survivor stories, as well as an increased use of social media. The focus for 2017 is to attract more institutional partners and increase the diversity of the participants, as well as broaden the global reach of the campaign.
Partners:

American Lung Association’s LUNG FORCE
Caring Ambassadors
Chris Draft Family Foundation
Clifton F. Mountain Foundation
Faces of Lung Cancer
Free ME from Lung Cancer
Free to Breathe
Global Resource for Advancing Cancer Education
IASLC
Live Lung
Lung Cancer Alliance
Lung Cancer Europe
Lung Cancer Foundation of America
Lung Cancer Initiative of North Carolina
Lung Cancer Research Foundation
Lung Cancer Social Media
LungCAN
Lungevity
Patient Power
Rexanna’s Foundation
The Bonnie J. Addario Lung Cancer Foundation
University of Colorado Cancer Center
Upstage Lung Cancer
Women Against Lung Cancer in Europe

Supporters:

Lilly | Oncology | Merck | Helsinn
COMMUNICATIONS

The IASLC’s communications efforts achieved new heights in 2016, garnering significant media attention for the organization. Over the course of the year, the IASLC published nearly 60 press releases, with subjects ranging from cutting-edge science and conference announcements, to award notices and organizational developments. This collective effort resulted in nearly 3,600 media mentions for the IASLC – an increase of approximately 44 percent from the previous year.

Other notable accomplishments included high profile articles and advertisements in USA Today, The New York Times, The Wall Street Journal, Government Gazette (Europe) and Asia Pacific Biotech News; actively promoting the IASLC’s efforts for Lung Cancer Awareness Month (LCAM); making a major communications impact at the IASLC 17th World Conference on Lung Cancer (WCLC); and greatly expanding the organization’s reach on social media.

In 2017, the IASLC will leverage its work from 2016 to further expand the impact of its communications activities. More specifically, the IASLC hopes to solidify its brand and core messaging; produce a strategic communications plan; and better publicize its meetings, publications and educational programs.

WORLD CONFERENCE ON LUNG CANCER

The IASLC 17th World Conference on Lung Cancer (WCLC 2016) was held in Vienna, Austria, on December 4-7, 2016. Communication efforts for the WCLC 2016 included coordinating media registrations, creating a digital press kit, composing nearly 30 press releases, managing daily press conferences, social media promotion and facilitating interviews between news organizations and key IASLC figures. These initiatives resulted in over three billion impressions, nearly 400 original stories, sizable gains in the IASLC’s social media accounts and a conference hashtag, #WCLC2016, which trended each day of the conference.

Overall, about 150 members of the media attended the conference, generating coverage of the IASLC in more than 40 countries. The conference and its proceedings were featured in print and online publications and a variety of other media outlets across the globe.
2016 SUMMARY

MEDIA MENTIONS: 3,600
2015-2016 CHANGE: +44.4%

SOCIAL MEDIA

+820 Twitter Follows
+606 Facebook Likes
+174 LinkedIn Likes

SPOTLIGHT ON THE IASLC 17th World Conference on Lung Cancer

3,000 MEDIA MENTIONS
3.5 BILLION IMPRESSIONS
400 ORIGINAL STORIES

JOURNALISTS FROM 40 COUNTRIES COVERED THE CONFERENCE

#WCLC2016
The WORLD CONFERENCE ON LUNG CANCER hashtag trended on Twitter every day of the conference
PUBLICATIONS

In order to collate vast amounts of information in the field of lung cancer, the IASLC has harnessed the expertise of our members and key opinion leaders to create a number of educational publications in 2016. These publications serve as resources for all of those involved in lung cancer, with the goal of raising awareness, setting global standards and ensuring that patients get the best possible care no matter where they live.

8th Edition of the Tumor, Node and Metastasis (TNM) Classification for Lung Cancer, Thymic Tumors and Mesothelioma

The IASLC staging classification, developed in collaboration with the American Joint Committee on Cancer and the Union for International Cancer Control, is utilized by physicians throughout the world to more precisely stage, manage and treat lung cancer and other thoracic malignancies and is also used as a basis for further research.

Completed in 2016, the 8th Edition of the International Staging of Thoracic Malignancies includes the IASLC Staging Manual in Thoracic Oncology (second edition), a unique volume that contains the latest revisions of the tumor, node and metastasis (TNM) classifications of thoracic malignancies, namely, lung cancer, malignant pleural mesothelioma, carcinoma of the esophagus and of the esophago-gastric junction and thymic epithelial tumors. An accompanying handbook and a set of 16 laminated reference cards was also published.

While the previous 7th edition of the staging system was focused on lung cancer, the new 8th edition includes staging of thymic cancers and mesotheliomas and is based on approximately 100,000 cases collected by international multidisciplinary investigators from all geographic regions of the world. This data-driven approach includes many innovations that will likely lead to changes in clinical practice.

IASLC Lung Cancer News

The IASLC Lung Cancer News (ILCN), launched in 2016 as a quarterly publication, acknowledges the complex interplay that exists among the broad spectrum of thoracic malignancy research, including diagnostics, screening, tobacco control, therapeutic interventions, quality of life, symptom management and survivorship. Now bi-monthly, the ILCN features expert commentary from thoracic oncology leaders, the industry at large and regulators. It presents the most recent and noteworthy lung cancer-related information to a worldwide audience. Additionally, themed issues center on particular topics or meetings and often tackle ongoing controversies and debates. ILCN’s goal is to facilitate professional development, bolster patient care and research, and, ultimately, improve clinical outcomes.
IASLC Atlas of ALK and ROS1 Testing in Lung Cancer

Since its initial publication in 2013, the IASLC Atlas of ALK Testing in Lung Cancer has been printed in four languages and continues to be widely requested throughout the world. However, in recent years the diagnosis and treatment of advanced lung cancer patients have undergone transformational changes, prompting an update to the Atlas to include information on ROS1 testing methodologies.

The IASLC Pathology Committee convened an expert panel to publish the second edition, the IASLC Atlas of ALK and ROS1 Testing in Lung Cancer. The Atlas is designed to serve as a resource to help pathologists, laboratory scientists and practicing physicians better understand the background, protocol and interpretation of results of ALK and ROS1 testing for patients with advanced non-small cell lung cancer. The Atlas was launched at the IASLC 17th World Conference on Lung Cancer and is now available via iOS and Android mobile apps.


Due to the rapid progress in lung cancer therapy and diagnosis, the IASLC convened a multidisciplinary expert panel to review and discuss the emerging scientific data pertaining to the contemporary management of epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer patients. From that expert panel came a consensus statement on optimizing the management of this unique subgroup of patients that was published in the Journal of Thoracic Oncology. This report addressed key pathologic, diagnostic and therapeutic considerations and made recommendations for clinical guidelines and research priorities, such as the treatment of progressive disease due to resistance, the management of brain metastases, the role of repeat biopsies and the use of circulating free DNA for molecular studies.
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

This 2016 publication was the result of a workshop of international experts sponsored by the IASLC and the National Cancer Institute (NCI) that convened to review and re-focus research efforts on small cell lung cancer (SCLC), an under-studied and NCI-designated “recalcitrant” cancer. This article addressed the recent developments in therapeutic opportunities, particularly targeted therapies, which have resulted from an increased understanding of the biology and molecular biology of this specific type of lung cancer. Studies of early lung and neuroendocrine models have provided insights into the cell of origin for SCLC, while molecular studies have identified the difference between SCLC and other lung cancer tumors. Potential therapeutic targets have been identified and it’s essential that ongoing and future clinical trials show which targets can best be translated into effective therapies.

IASLC-Genentech Cooperative Project

In 2016, the IASLC and Genentech partnered to assess patient experiences related to their lung cancer diagnoses. Access to cancer specialists, gene mutation testing and treatment options was analyzed by using healthcare claims data from MarketScan and SEER-Medicare databases.

The objective was to understand referral patterns and rates from diagnosing physician to oncologist; biomarker testing patterns and rates; adequacy of lung cancer tissue for biomarker testing; turnaround time from tissue biopsy to known molecular status; and systemic treatment rates in first-time, advanced non-small cell lung cancer.

This study resulted in multiple presentations and publications, including posters at the 2016 American Society of Clinical Oncology Annual Meeting (title: “Access to Specialist Care and Treatment in Patients with Advanced Non-Small Cell Lung Cancer”) and the IASLC 17th World Conference on Lung Cancer in 2016 (title: “Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer”). Additionally, several related manuscripts are currently in preparation and under review for publication.

Scientific Advances in Lung Cancer 2015 (published in 2016)

Capturing and summarizing the remarkable progress in lung cancer prevention, diagnosis, staging and treatment in 2015, the IASLC published Scientific Advances in Lung Cancer 2015 in the Journal of Thoracic Oncology.

Drawing on the knowledge, research and practice of dozens of multidisciplinary experts from around the globe, the IASLC introduced this valuable educational resource in order to keep busy practitioners, scientists and others interested in lung cancer up-to-date on the latest breakthroughs. As lung cancer therapy has emerged as a role model for precision cancer medicine, the publication focuses on the following areas: prevention and early detection, stages I-III non-small cell lung cancer, pathology, staging, the role of surgery and the role of adjuvant chemotherapy.
JOURNAL OF THORACIC ONCOLOGY

The Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer (IASLC), is the primary educational and informational publication for topics relevant to the detection, prevention, diagnosis and treatment of thoracic malignancies. The JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews and opinion pieces. It has a global author base and readership consisting of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists and research scientists with a special interest in thoracic oncology.

Submissions to the Journal of Thoracic Oncology increased by 11 percent in 2016 – 994 original research articles were submitted and 168 were accepted, resulting in an acceptance rate of 16.9 percent. For all submission types, 1,441 manuscripts were submitted and 247 were accepted (17.1 percent). Journal website traffic increased 13 percent over 2015. The JTO was ranked 33rd out of 213 for Oncology and seventh out of 58 for Respiratory System subject matter categories in the 2015 Journal Citation Reports. The 2015 Impact Factor was 5.040. The JTO is published in English, French, Italian and Korean.

The JTO maintains a quick turnaround time of less than 10 days and publishes articles online within three to five days of acceptance. Articles of high scientific interest receive fast track designation, are reviewed within 48 hours and published online within three to five days.

These statistics highlight the JTO’s successful partnership with education publisher Elsevier, which began publishing the Journal in 2016. This collaboration offers many opportunities for authors and readers. During 2016, authors had opportunities to promote their own work, receiving a link for their published articles. This Share Link provides authors access to their articles for 50 days and allows them to email the link to co-authors and colleagues, post on a personal webpage and share on social media. Authors can also create AudioSlide presentations to accompany their articles and augment their impact.

Another Elsevier enhancement is the Interactive Pathway Viewer, which automatically displays interactive pathways next to articles on ScienceDirect. Each article that has a pathway is processed automatically using MedScan for proteins, genes, chemical compounds, etc. These are converted into pathway diagrams based on their relationships. The Interactive Pathway Viewer enables authors to enrich their articles with visual pathway information, without the need to submit additional files.

Looking further ahead, the JTO anticipates taking advantage of additional Elsevier enhancements such as the Virtual Microscope. The Virtual Microscope lets authors complement conventional, in-article images with large high-resolution equivalents. It is fully integrated with ScienceDirect and journal sites. The in-article viewer is fully interactive and enables users to zoom in and navigate within images. It can also be used in full screen mode.

The JTO offers Continuing Medical Education (CME) credit for manuscript reviewers. In addition, JTO readers have the opportunity to obtain CME credit for reading one article per issue.

The IASLC continues its efforts to promote the JTO through press releases and social media, resulting in coverage in major media outlets worldwide.
MEETINGS

The staff and members of the International Association of the Study of Lung Cancer (IASLC) work to enhance the understanding of lung cancer and other thoracic malignancies among scientists, members of the medical community and the public. One of the most effective ways is by offering leading-edge educational meetings around the globe.

IASLC meetings provide an excellent opportunity for exchanging scientific advances and clinical experiences with colleagues, as well as for initiating or strengthening collaboration. This exchange of information and knowledge ultimately benefits patients with lung cancer worldwide.

IASLC 17TH WORLD CONFERENCE ON LUNG CANCER

The IASLC World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 6,500 delegates from nearly 100 countries attended the 2016 event held in Vienna, Austria, to discuss the latest developments in thoracic malignancy research.

With the theme of “Active Prevention, Accurate Diagnosis, Advanced Care,” the multidisciplinary conference saw surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, research scientists, nurses, allied health professionals and patients come together as one global force to learn about the latest scientific advances, to network with colleagues and to continue the global conversation and exchange of information. In addition, patients, advocates and members of the pharmaceutical industry had the opportunity to interact with researchers and clinicians on the front lines of cancer science and cancer care.

Major topics included global tobacco control, screening and early detection, staging, molecular diagnosis, extended surgical procedures, advances in radiation therapy, targeted therapies and immunotherapy, with an emphasis on immune checkpoint inhibitors.

Advances in lung cancer research were presented in plenary sessions, scientific sessions, oral and mini-oral sessions, as well as poster sessions. The conference also provided updates on the state-of-the-art management of lung cancer.
### CONFERENCE PRESIDENT: Robert Pirker, Austria

### REGIONAL ORGANIZING COMMITTEE

<table>
<thead>
<tr>
<th>Otto Chris Burghuber, Austria</th>
<th>Martin Filipits, Austria</th>
<th>Christian Herold, Austria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wolfgang Hilbe, Austria</td>
<td>Walter Klepetko, Austria</td>
<td>Michael Rolf Muller, Austria</td>
</tr>
<tr>
<td>Gyula Ostoros, Hungary</td>
<td>Lubos Petruzelka, Czech Republic</td>
<td>Helmut Popper, Austria</td>
</tr>
<tr>
<td>Richard Potter, Austria</td>
<td>Herbert Watzke, Austria</td>
<td>Christoph Zielinski, Austria</td>
</tr>
<tr>
<td>Sabine Zochbauer-Muller, Austria</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 2016 IASLC MEETINGS

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Location</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fourth AACR (American Association for Cancer Research)-IASLC International Joint Conference</td>
<td>January 4-7, 2016</td>
<td>San Diego, California, USA</td>
<td>300 participants</td>
</tr>
<tr>
<td>16th Annual Targeted Therapies of the Treatment of Lung Cancer</td>
<td>February 17-20, 2016</td>
<td>Santa Monica, California, USA</td>
<td>450 participants</td>
</tr>
<tr>
<td>European Lung Cancer Conference</td>
<td>April 13-16, 2016</td>
<td>Geneva, Switzerland</td>
<td>2,000 participants</td>
</tr>
<tr>
<td>Asia Pacific Lung Cancer Conference</td>
<td>May 13-15, 2016</td>
<td>Chiang Mai, Thailand</td>
<td>800 participants</td>
</tr>
<tr>
<td>Latin America Lung Cancer Conference</td>
<td>August 25-27, 2016</td>
<td>Panama City, Panama</td>
<td>500 participants</td>
</tr>
<tr>
<td>Multidisciplinary Symposium in Thoracic Oncology</td>
<td>September 22-24, 2016</td>
<td>Chicago, Illinois, USA</td>
<td>450 participants</td>
</tr>
<tr>
<td>17th World Conference on Lung Cancer</td>
<td>December 4-7, 2016</td>
<td>Vienna, Austria</td>
<td>6,500 participants</td>
</tr>
</tbody>
</table>

### 2017 IASLC MEETINGS

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>17th Annual Targeted Therapies of the Treatment of Lung Cancer</td>
<td>February 22-25, 2017</td>
<td>Santa Monica, California, USA</td>
</tr>
<tr>
<td>Small Cell Lung Cancer Workshop</td>
<td>March 15-17, 2017</td>
<td>New York, New York, USA</td>
</tr>
<tr>
<td>European Lung Cancer Conference</td>
<td>May 5-8, 2017</td>
<td>Geneva, Switzerland</td>
</tr>
<tr>
<td>Multidisciplinary Symposium in Thoracic Oncology</td>
<td>September 14-16, 2017</td>
<td>Chicago, Illinois, USA</td>
</tr>
<tr>
<td>18th World Conference on Lung Cancer</td>
<td>October 15-18, 2017</td>
<td>Yokohama, Japan</td>
</tr>
</tbody>
</table>
IASLC 18TH WORLD CONFERENCE ON LUNG CANCER:
CURE THROUGH SYNERGY

October 15-18, 2017
PACIFICO Yokohama Convention Center
Yokohama, Japan

Conference Presidents
Hisao Asamura, Japan
Keunchil Park, South Korea

REGIONAL ORGANIZING COMMITTEE
Akihiko Gemma, Japan
Norihiko Ikeda, Japan
Kaoru Kubota, Japan
Tetsuya Mitsudomi, Japan
Kazuhiro Nakagawa, Japan
Yuko Nakayama, Japan
Yuichiro Ohe, Japan
Ikuo Sekine, Japan
Shun-ichi Watanabe, Japan
Yasushi Yatabe, Japan

Myung-Ju Ahn, South Korea
Young Tae Kim, South Korea
Young Taek Oh, South Korea
Jeong-Seon Ryu, South Korea
EDUCATIONAL ACTIVITIES

The IASLC highly values education and serves as a key resource for lifelong learning and professional growth by providing opportunities for physicians, scientists and other health professionals to learn about the latest scientific advances and apply that knowledge to their patients and practices worldwide.

The IASLC expanded its Continuing Medical Education (CME) accredited programs in 2016. The CME webinar series, workshops and live learning events are designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including but not limited to medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants. All IASLC CME programs are accredited by the Accreditation Council for Continuing Medical Education (ACCME).

Featuring expert-driven content, educational offerings are multidisciplinary and cover all aspects of the management of lung cancers, mesothelioma and other thoracic malignancies. Sessions take place throughout the world – in-person and online – and are designed to enrich IASLC members both personally and professionally.

The IASLC’s steadfast commitment to learning continues in 2017 with further expansion of its offerings, including the IASLC Academy, a new initiative for young specialists slated to launch later in the year, as well as a series of workshops for thoracic oncology nurses.

IASLC WEBINAR PROGRAM – 2016

New Frontiers in the Management of Lung Cancer
Speakers: Tony Mok, MD, PhD – Hong Kong
         Nayer Rizvi, MD – USA
         Daniel S. W. Tan, MD – Singapore
Date: January 7, 2016

IASLC European Webinar Series – Immunotherapy for Lung Cancer
Speakers: Mary O’Brien, MD, PhD – United Kingdom
Date: January 13, 2016

IASLC European Webinar Series – Advances in Radiotherapy for Lung Cancer
Speakers: Francoise Mornex, MD, PhD – France
Date: January 20, 2016

Taking Bites of the KRAS Pie – Co-occurring Mutations Define KRAS Subsets with Distinct Biology, Immune Profiles and Drug Vulnerabilities
Speakers: John Heymach, MD – USA
         Ramaswamy Govindan, MD – USA
Date: January 27, 2016

IASLC European Webinar Series – Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Speakers: Wilfried Ernst Erich Eberhardt, MD – Belgium
Date: February 10, 2016
### Proton Beam Therapy for Lung Cancer

**Speakers:** Francoise Mornex, MD, PhD – France  
Ramesh Rengan MD, PhD – USA  
Tony Wong, PhD, DABR – USA  

**Date:** February 12, 2016

### The Evolving Landscape of Small Cell Lung Cancer Therapy

**Speakers:** Lauren Averett Byers, MD – USA  
Ramaswamy Govindan, MD – USA  

**Date:** March 9, 2016

### IASLC European Webinar Series – Treatment of Squamous Cell Non-Small Cell Lung Cancer: What’s New?

**Speakers:** Giorgio V. Scagliotti, MD – Italy  

**Date:** March 10, 2016

### Centrally Located Early-Stage Lung Cancer: When and How to Perform Stereotactic Ablative Radiotherapy (SABR)

**Speakers:** Francoise Mornex, MD, PhD – France  
Suresh Senan, MD, PhD, FRCP – Netherlands  
Wilko Verbakel, PhD, Ir, PDEng – Netherlands  

**Date:** March 24, 2016

### IASLC European Webinar Series – Treatment of ALK-Positive Non-Small Cell Lung Cancer

**Speakers:** Lucio Crino, MD, PhD – Italy  

**Date:** April 19, 2016

### IASLC European Webinar Series – Management of TKI Resistance in Non-Small Cell Lung Cancer

**Speakers:** Federico Cappuzzo, MD – Italy  

**Date:** May 11, 2016

### Radiation Oncology Highlights – European Lung Cancer Conference (ELCC) and European Society for Radiotherapy & Oncology (ESTRO) meetings

**Speakers:** Francoise Mornex, MD, PhD – France  
Jose Belderbos, MD, PhD – Netherlands  

**Date:** May 26, 2016

### IASLC European Webinar Series – Optimal Utilization of Anti-Angiogenesis Therapy for Non-Small Cell Lung Cancer

**Speakers:** Martin Reck, MD, PhD – Germany  

**Date:** June 23, 2016

### IASLC Lung Cancer Grand Rounds – Advances in Treatment of Lung Cancer

**Speakers:** Mark A. Socinski, MD – USA  
Ramaswamy Govindan, MD – USA  

**Date:** June 28, 2016

### Implementing and Integrating a CT Screening and Smoking Cessation Program

**Speakers:** Jamie S. Ostroff, PhD – USA  
Debra S. Dyer, MD, FACR – USA  
James Jett, MD – USA  

**Date:** June 30, 2016
## IASLC WEBINAR PROGRAM – 2016 CONTINUED

### Treatment of Patients with EGFR-Mutant Non-Small Cell Lung Cancer
- **Speakers:** Federico Cappuzzo, MD – Italy
- **Date:** July 5, 2016

### Radiation Oncology Highlights – American Society of Clinical Oncology (ASCO) Annual Meeting
- **Speakers:** Corinne Faivre-Finn, MD – United Kingdom
  - Maria Werner-Wasik, MD, FASTRO – USA
  - Francoise Mornex, MD, PhD – France
- **Date:** July 7, 2016

### Malignant Pleural Mesothelioma – Multidisciplinary Treatment Update
- **Speakers:** Joseph S. Friedberg, MD, FACS – USA
  - Anne S. Tsao, MD – USA
- **Date:** July 27, 2016

### IASLC Lung Cancer Grand Rounds – Advances in Lung Cancer Imaging
- **Speakers:** Brett W. Carter, MD – USA
  - Ramaswamy Govindan, MD – USA
- **Date:** August 16, 2016

### Management of ALK Patients with Non-Small Cell Lung Cancer – A Multidisciplinary Approach
- **Speakers:** Alice Shaw, MD – USA
  - Lynette Sholl, MD – USA
  - Leora Horn, MD – USA
- **Date:** September 12, 14 and 16, 2016

### Mesothelioma – Causes, Prevention, Screening and Early Detection
- **Speakers:** Harvey I. Pass, MD – USA
  - Michele Carbone, MD – USA
- **Date:** November 15, 2016

### IASLC Chicago Multidisciplinary Symposium and European Society of Medical Oncology (ESMO) 2016 Annual Meeting Updates
- **Speakers:** Thomas Stinchcombe, MD – USA
  - Ramaswamy Govindan, MD – USA
- **Date:** November 16, 2016

### Emerging Therapy Options in Immunotherapy for Non-Small Cell Lung Cancer
- **Speakers:** Sarah Goldberg, MD – USA
  - Ramaswamy Govindan, MD – USA
- **Date:** December 20, 2016

## IASLC LIVE LEARNING EVENTS AND WORKSHOPS

### Workshop in Lung Cancer for Latin America Region
- **Speakers:** Fred R. Hirsch, MD, PhD – USA
  - Christian Rolfo, MD, PhD, MBA – Belgium
  - Christian Caglevic, MD – Chile
- **Date:** April 28-30, 2016
- **Location:** Santiago, Chile
Multidisciplinary Hands-On Live Learning: Molecular Testing and Personalized Therapy in Lung Cancer

Speakers: David Berkowitz, MD - USA
Sanja Dacic, MD - USA
Anthony Gal, MD - USA
Kristin Higgins, MD - USA
Corey Langer, MD - USA
Christopher Manley, MD - USA
Harvey Pass, MD - USA
Jyoti Patel, MD - USA
Matthew Steliga, MD - USA

Date/Location
October 14, 2016/Chicago, Illinois, USA
October 21, 2016/Philadelphia, Pennsylvania, USA

Disciplines Covered: Pathology, Medical Oncology, Radiation Oncology, Pulmonology, Surgery

BEST OF THE IASLC WORLD CONFERENCE ON LUNG CANCER – 2016

The IASLC World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. The IASLC recognizes that not everyone is able to attend the conference in person and, in response, created the Best of WCLC educational series.

An educational initiative designed to engage researchers and practitioners, the Best of WCLC 2016 condenses the timeliest scientific and broad-spectrum topics into a one- or two-day event consisting of six to eight hours a day of educational sessions. Presented by regional teams recruited from multiple disciplines, the Best of WCLC brings the top abstracts from the conference to thoracic oncology professionals, live, at their location. The abstracts are carefully chosen by experts on the WCLC Scientific Program Committee.

A TOTAL OF 17 BEST OF WCLC 2016 EVENTS TOOK PLACE IN THE FOLLOWING COUNTRIES IN LATE 2016 AND EARLY 2017:
EXCITING NEW TASK FORCE AND COMMITTEE INITIATIVES

A highly effective means for IASLC members to get involved and make an impact is by serving on a committee or task force. Members donate their time, talents and resources and very often play a significant role in advancing the organization’s mission. A complete list can be found on pages 32-33.

Here are just a few of the projects they’re working on.

NURSES AND ALLIED HEALTH PROFESSIONALS COMMITTEE

In order to reach, educate and learn from the entire multidisciplinary team involved in lung cancer research and care, the IASLC recognizes the crucial role that nurses and allied health professionals play in public education and patient care. To that end, the IASLC’s Nurses and Allied Health Professionals Committee continues to reach out to nurses and others caring for patients worldwide.

An important initiative was established at the IASLC 17th World Conference on Lung Cancer: The Thoracic Oncology Nursing and Allied Health Workshop. At this workshop, the first of its kind, guidelines were developed for the management of immunotherapy side effects. The group identified the need for an evidence-based guide to support nurses and other health providers in managing side effects, which differ from those associated with chemotherapy and other traditional lung cancer treatments. It is expected the guide will be available for distribution in 2017.

PATIENT ADVOCATES COMMITTEE

Because it’s vital for the lung cancer patient’s voice to be heard, the Patient Advocates Committee addresses the need for communication between doctors and patients and works to disseminate the latest patient care information to the general public. Committee members also serve as liaisons between the IASLC and patient advocacy organizations. Since its initial recommendation in 2011 to offer World Conference on Lung Cancer travel scholarships, the committee has provided funding to 21 lung cancer and mesothelioma patient advocates, many of whom are lung cancer survivors.

Patient Advocates Committee members also played an integral role in the Lung Cancer Awareness Month harmonized strategy in November 2016, which was led by the IASLC. This initiative involved the collaboration of more than 20 advocacy organizations in the U.S. and Europe.

PREVENTION, SCREENING AND EARLY DETECTION COMMITTEE

There is enormous potential for the future integration of validated biomarkers when selecting high-risk individuals into national screening programs. Thanks to the members and chairs of the Prevention, Screening and Early Detection Committee for their work on the idea of an IASLC Confederation of Computed Tomography (CT)-Screened Patients’ Registry and Resource Center (IASLC-CCTRR) and for their continual efforts toward establishing clear and effective screening programs worldwide.

SMOKING CESSATION AND TOBACCO CONTROL COMMITTEE

This committee is largely engaged in educating patients and healthcare providers on the adverse effects of tobacco use and the benefits of cessation while also addressing the development and marketing of alternative tobacco products like electronic cigarettes.
Committee members also stay up-to-date on tobacco legislation worldwide. The tireless advocacy of this committee is evident in the recently completed traveling display depicting the history of tobacco products and the industry. The highly-informative display clearly demonstrates the dangers of tobacco use.

**IASLC/ASCO THORACIC ONCOLOGY QUALITY AND VALUE TASK FORCE**

Ensuring that patients get the best quality of care has long been an IASLC standard. The high cost of recently approved drugs for thoracic malignancies has heightened the importance of value as a consideration in treatment decisions and has placed lung cancer at the center of emerging and evolving paradigms of care delivery. Through the IASLC/American Society of Clinical Oncology (ASCO) Task Force, lung cancer experts play an integral role in defining optimal quality metrics that will be used to reimburse physicians for the cancer care they provide.

**MESOTHELIOMA TASK FORCE**

Recognizing the need to increase the visibility and awareness of mesothelioma, the new IASLC Mesothelioma Task Force was created to fully integrate mesothelioma into the IASLC scientific portfolio. Hitting the ground running, the task force has created content for the IASLC 16th and 17th World Conferences on Lung Cancer, for webinars and other educational activities, manuscripts and more.

**MOLECULAR DATABASE TASK FORCE**

The Molecular Database Task Force is focused on creating a database with information about common molecular aberrations found in non-small cell lung cancer patients for use by clinicians worldwide. Research suggests that molecular markers might be different based on ethnicity, geography, demographics, histology and stage. The goal of the database is to ensure better treatment options for patients.
CAP/IASLC/AMP MOLECULAR TESTING GUIDELINE FOR SELECTION OF LUNG CANCER PATIENTS

The College of American Pathologists (CAP), the IASLC and the Association for Molecular Pathology (AMP) convened an expert panel to review and update the 2013 guideline and, through a systematic review of the literature, developed new, evidenced-based recommendations for the molecular testing of lung cancer. The manuscript is currently being finalized, with an expected mid-2017 publication in the *Journal of Thoracic Oncology* and accompanying documentation to follow.

PD-L1 BLUEPRINT

Focused on gaining a better understanding of the analytical and clinical comparability of four PD-L1 assays used in clinical trials, the PD-L1 Blueprint project is a unique industrial-academic collaboration between the IASLC and members of its Pathology Committee, the American Association for Cancer Research, five pharmaceutical companies and two diagnostic companies. Phase I was completed in 2016 and a manuscript will be published in the *Journal of Thoracic Oncology*. Funding for a PD-L1 Atlas has been secured and the IASLC Pathology Committee expects to finalize it in 2017. Work on Phase II has begun and includes a larger series of tumors and several new analyses.

IASLC COMMITTEES 2016-2017

<table>
<thead>
<tr>
<th>COMMITTEE</th>
<th>CHAIR(S)</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awards</td>
<td>David Carbone</td>
<td>The Awards Committee selects the recipients of the various IASLC distinguished awards presented each year at the IASLC World Conference on Lung Cancer.</td>
</tr>
<tr>
<td>Career Development &amp; Fellowship</td>
<td>Carlos Gil Ferreira, Benjamin Solomon</td>
<td>The Career Development Committee helps IASLC members progress through their career, often acting in a mentor capacity for early-career professionals.</td>
</tr>
<tr>
<td>Communications</td>
<td>Ross Soo</td>
<td>The Communications Committee works to bolster the IASLC’s brand. Its initiatives educate the medical community and public about complex cancer issues. Committee members also assist in planning the press program for the IASLC World Conference on Lung Cancer and serve as spokespersons for the organization.</td>
</tr>
<tr>
<td>Education</td>
<td>Federico Cappuzzo</td>
<td>The Education Committee plans, develops, initiates and reviews the IASLC’s educational programs, with special emphasis placed on programming for the IASLC World Conference on Lung Cancer.</td>
</tr>
<tr>
<td>Advanced Radiation Therapy (sub-committee of the Education Committee)</td>
<td>Laurie Gaspar, Francoise Mornex</td>
<td>The Advanced Radiation Therapy Committee develops educational content to help radiation oncologists around the world understand the important role of radiation therapy in the treatment of lung cancer.</td>
</tr>
<tr>
<td>Continuing Medical Education (sub-committee of the Education Committee)</td>
<td>Ramaswamy Govindan</td>
<td>The Continuing Medical Education Committee guides the development of educational activities aimed at furthering the knowledge, skills and professional performance of medical professionals engaged in thoracic cancers.</td>
</tr>
<tr>
<td>Ethics</td>
<td>Thierry Marie Jahan</td>
<td>The Ethics Committee guides the development and review of the IASLC Member and Board of Directors’ Code of Ethical Conduct.</td>
</tr>
<tr>
<td>COMMITTEE</td>
<td>CHAIR(S)</td>
<td>DESCRIPTION</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Finance</td>
<td>David Gandara</td>
<td>The Finance Committee oversees the fiscal management of the association and its affiliated organizations. It also oversees the performance of IASLC investments and annually reviews the association’s risk management and insurance program.</td>
</tr>
<tr>
<td>Membership</td>
<td>Luis Raez</td>
<td>The Membership Committee, acting in accordance with the IASLC Bylaws, reviews and makes recommendations for the membership status of regular members, senior members, fellows and allied health professionals and strategizes ways to increase and retain IASLC’s membership base. The committee also engages in joint promotions with complementary societies and organizations.</td>
</tr>
<tr>
<td>Nominations</td>
<td>David Gandara</td>
<td>The Nominating Committee develops potential candidates for elected positions within the IASLC, including president-elect, treasurer and board of directors, in accordance with the bylaws.</td>
</tr>
<tr>
<td>Nurses &amp; Allied Professionals</td>
<td>Anne Fraser, John White</td>
<td>The Nurses and Allied Professionals Committee ensures the IASLC addresses the educational needs of thoracic oncology professionals.</td>
</tr>
<tr>
<td>Pathology</td>
<td>Yasushi Yatabe</td>
<td>The Pathology Committee helps guide the IASLC’s integrated clinical, radiologic, molecular and pathologic approach to the classification of lung and thoracic cancers.</td>
</tr>
<tr>
<td>Patient Advocacy</td>
<td>Glenda Colburn</td>
<td>The Patient Advocacy Committee ensures the IASLC effectively communicates important information on thoracic oncology to patients, advocates and the general public.</td>
</tr>
<tr>
<td>Prevention, Screening &amp; Early Detection</td>
<td>John Field, Nir Peled</td>
<td>The Prevention, Screening and Early Detection Committee leads the IASLC’s prevention, screening and early detection initiatives and partners with other medical societies and advocacy organizations on similar programs.</td>
</tr>
<tr>
<td>Publications</td>
<td>David Spigel</td>
<td>The Publications Committee oversees IASLC publications, including the <em>Journal of Thoracic Oncology</em> (JTO), the <em>IASLC Lung Cancer News</em> and others.</td>
</tr>
<tr>
<td>Staging</td>
<td>Ramon Rami-Porta</td>
<td>The Staging Committee participates in the study and improvement of cancer staging systems relevant to thoracic oncology and directs the collection and analysis of patient information while periodically updating staging systems.</td>
</tr>
<tr>
<td>Tobacco Control &amp; Smoking Cessation</td>
<td>Graham Warren</td>
<td>The Tobacco Control and Smoking Cessation Committee ensures the IASLC addresses the needs of practitioners seeking to help their patients stop tobacco use by contributing to local, national and international efforts in tobacco control initiatives and interventions.</td>
</tr>
</tbody>
</table>
2016 Paul A. Bunn, Jr. Scientific Award

The Paul A. Bunn, Jr. Scientific Award recognizes IASLC scientists for lifetime achievement in scientific contributions to thoracic cancer research. Robert Ginsberg, MD, a thoracic surgeon from Toronto, Canada, earned the first award in 1994 for his contributions to the surgical treatment of early stage lung cancer. The IASLC named the award after Dr. Paul Bunn in 2013 when he stepped down after serving as its Executive Director/CEO for 10 years.

ROY S. HERBST, MD, PhD

Roy S. Herbst, MD, PhD, is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut, USA.

Dr. Herbst has worked tirelessly to bring novel targeted agents to clinical trials and ultimately to U.S. Federal Drug Administration (FDA) approval, leading clinical trials to test these agents in advanced stage non-small cell lung cancer (NSCLC) and other cancers.

One of Dr. Herbst’s most significant accomplishments has been the progress made in promoting individualized, biopsy-driven therapy. The BATTLE trial, which he co-led, was the first prospective, adaptively randomized study in heavily pretreated patients with NSCLC.

As a follow-on study, Dr. Herbst led a group that initiated the ongoing Lung Master Protocol (Lung MAP), a clinical trial designed to identify patients with advanced squamous cell lung cancer who have specific gene mutations in their tumors and treat them with the most relevant therapy targeting those mutations.

More recently, Dr. Herbst has made significant breakthroughs in immunotherapy. Research from his group and others aided in the U.S. FDA’s approval of atezolizumab and pembrolizumab for NSCLC.

Dr. Herbst is an American College of Physicians Fellow, a member of the American Society of Clinical Oncology, an elected member of the Association of American Physicians and a member of the American Association for Cancer Research, where he chairs the Tobacco Task Force. He was also a member of the National Cancer Policy Forum from 1998 to 2014. He has authored or co-authored more than 250 publications, including peer-reviewed journal articles, abstracts and book chapters.
Joseph W. Cullen Prevention/Early Detection Award

The Joseph W. Cullen Prevention/Early Detection Award recognizes IASLC scientists for lifetime achievement in the prevention of thoracic malignancies. Dr. Cullen served as the Deputy Director of the National Cancer Institute’s (NCI) Division of Cancer Prevention and Control. He created the Smoking, Tobacco and Cancer Program at the NCI in 1982. The winner of the first award in 1994 was Jesse Steinfeld, MD, the U.S. Surgeon General when the National Cancer Act of 1971 was enacted into federal law.

UGO PASTORINO, MD

Ugo Pastorino, MD, is Director of the Thoracic Surgery Division at the Istituto Nazionale dei Tumori in Milan, Italy. The division was the first comprehensive cancer center in Italy to deal with thoracic oncology and is a national referral center for the treatment of highly complex chest cancer.

Dr. Pastorino pioneered early studies of chemoprevention of smoking-induced cancers, focusing on such agents as vitamin A (retinol) and synthetic derivatives. In 1985, he launched the first randomized trial on adjuvant treatment of stage I lung cancer with vitamin A, which showed a significant reduction of second primary lung cancer.

In 1991, he launched the International Registry of Lung Metastases to help the field of thoracic oncology assess the long-term results of pulmonary metastasectomy, define prognostic factors and propose a new system of classification based on long-term survival.

Dr. Pastorino’s clinical research interests lie in the diagnosis and treatment of primary and secondary lung cancer, use of positron emission tomography for staging thoracic malignancies, salvage surgery of lung metastases and mediastinal tumors, biology of lung carcinogenesis and chemoprevention of smoking-induced cancers. He is a principal investigator on three ongoing prospective trials examining lung cancer screening with low-dose computed tomography and microRNA and the role of pleurectomy/decortication in the treatment of pleural mesothelioma.

Dr. Pastorino is a scientific reviewer for several journals, has served as an Associate Editor of the Journal of the National Cancer Institute since 2001 and has been Editor-in-Chief of Tumori since 2014.
Mary J. Matthews Pathology/Translational Research Award

The Mary J. Matthews Pathology/Translational Research Award recognizes an IASLC scientist for lifetime scientific achievements in pathology-translational research of thoracic malignancies. Dr. Matthews was a Senior Investigator and Pathologist at the National Cancer Institute’s Medical Oncology Branch and the first to recognize that small cell lung cancer was disseminated at the time of diagnosis, leading to distinctions between small cell lung cancer and non-small cell lung cancer.

KEITH KERR, BSc, MB, ChB, FRCPath, FRCPEd

Keith Kerr, BSc, MB, ChB, FRCPath, FRCPEd, is Honorary Professor of Pulmonary Pathology at Aberdeen University Medical School in Aberdeen, Scotland, U.K. For over 35 years, Dr. Kerr has worked in diagnostic histopathology, with a special interest in thoracic pathology and thoracic medicine, particularly oncology.

Dr. Kerr studies pulmonary preneoplasia and carcinogenesis, tumor diagnosis and classification and the identification of predictors of response to therapy, and is particularly dedicated to lung cancer classification and treatment guidelines.

He served on the 2004 and 2015 World Health Organization’s lung cancer classification committees and is currently helping to revise the British Thoracic Society’s mesothelioma guidelines. Dr. Kerr is also assisting with revisions to the molecular pathology testing guidelines put forth by the College of American Pathologists, the IASLC and the Association for Molecular Pathology. Additionally, in 2011, Dr. Kerr was part of a collaborative group from the IASLC, the American Thoracic Society and the European Respiratory Society that developed an international, multidisciplinary classification of lung adenocarcinoma which accounts for almost half of all lung cancers.

Dr. Kerr is a contributing author to the second edition of the IASLC Atlas of ALK Testing in Lung Cancer; the IASLC Atlas of ALK and ROS1 Testing in Lung Cancer, published in 2016; and the IASLC PD-L1 Atlas, which is currently in development. He is also an Associate Editor for the Journal of Thoracic Oncology.

MERIT AWARDS

The IASLC Merit Award recognizes members who have made an extraordinary contribution to the organization’s development. The first recipient was Clifton Mountain, MD, in 1991. A pioneer in thoracic surgery, Dr. Mountain was world-renowned for his development of the international staging system for the classification of lung cancer. He was also a co-founder of the IASLC.

2016 IASLC Merit Award

SUMITRA THONGPRASERT, MD

Oncologist Sumitra Thongprasert is a Professor Emeritus on the Faculty of Medicine at Chiang Mai University in Thailand, a Senior Consultant in Oncology at Bangkok Hospital in Chiang Mai and Director of the hospital’s Center of Excellence in Cancer. Her research interests include lung cancer quality of life, chemotherapy and targeted therapy for lung cancer and biliary tract cancer.

Dr. Thongprasert actively fosters thoracic oncology education and collaboration in Southeast Asia. She is a founding member of the Thai Society of Clinical Oncology (TSCO), serving as its President from 2002 to 2006. She was also a founding member of the Asia Pacific Lung Cancer Group in 2004 and the Asia Pacific Lung Cancer Conference (APLCC), a biennial event hosted by the IASLC, TSCO, Chiang Mai Lung Cancer Group, Faculty of Medicine at Chiang Mai University and a local organizing committee. She chaired the inaugural conference in 2004 and the 2016 event, and is currently the chair of the IASLC APLCC Committee.
Dr. Thongprasert served on the IASLC Board of Directors from 2011 to 2015 and currently serves as Special Content Editor for the IASLC’s *Journal of Thoracic Oncology*. A member of the European Society for Medical Oncology (ESMO), she participated on its Developing Country Task Force from 2005 to 2010, was an ESMO Far East Regional Representative from 2008 to 2015 and will serve on the ESMO Executive Board in 2017-2018.

Dr. Thongprasert is a role model for female oncologists, promoting career development and consideration for leadership positions. To honor this work, ESMO presented her with its Women for Oncology Award, which acknowledges individuals who have significantly supported women in oncology.

Dr. Thongprasert received her undergraduate and medical degrees at Chiang Mai University. After that, the Anandamahidol Foundation in Thailand awarded her a scholarship to train as a fellow in hematology-oncology at Memorial Sloan-Kettering Cancer Center in New York, N.Y., USA. She then returned to her alma mater, Chiang Mai University, to establish the Medical Oncology Unit. She served as Professor of Oncology from 1999 to 2012 before being named Professor Emeritus.

**2016 IASLC Merit Award**

**KEUNCHIL PARK, MD, PhD**

Keunchil Park, MD, PhD, is a Professor in the Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine in Seoul, South Korea. He also serves as Director of the Institute for Innovative Cancer Medicine at Samsung Medical Center. Dr. Park’s professional interests lie in experimental and translational research in lung, head and neck and esophageal cancers; early clinical trials; and the development of experimental therapeutics. The institute he leads focuses heavily on data management and clinical and preclinical trials, particularly precision medicine and genome analysis.

He and his team have made significant progress in establishing a workflow for precision medicine and a multiplex molecular screening platform and activation of multiple umbrella clinical trials. Additionally, his team demonstrated that genome-matched treatment based on molecular profiling resulted in better treatment outcomes in terms of response rate.

A regional leader in oncology, Dr. Park has served as Chair of the Scientific Committee of the Korean Cancer Association, Chair of the Lung Cancer Committee of the Korean Cancer Study Group, Chair of the Board of Directors of the Korean Association for Clinical Oncology and President of the IASLC 2010 Asia Pacific Lung Cancer Conference (APLCC). He also serves as a member of the APLCC Committee. Recently, he initiated the Korea Actionable Genome Consortium under the auspices of the Korean Cancer Association.

Internationally, Dr. Park was the Scientific Secretary of the IASLC World Conference on Lung Cancer in 2007 and served on the IASLC Board of Directors from 2009 to 2013. He is also Co-President of the IASLC 18th World Conference on Lung Cancer to be held in Yokohama, Japan, in October 2017. Also in 2017, Dr. Park will host the International Cancer Genome Consortium (ICGC) workshop in Seoul. He is the Organizing Chair of the event and has been a member of the ICGC International Scientific Steering Committee since 2013. The workshop will provide a forum for international cancer communities to discuss common problems and share lessons learned.

Dr. Park earned his undergraduate degree, medical degree and doctorate from Seoul National University, and specializes in medical oncology. He also studied in the United States as a Visiting Associate with the National Cancer Institute.
IASLC FELLOWSHIP AND YOUNG INVESTIGATOR AWARDS

The IASLC supports young researchers by rewarding scientific excellence and encouraging innovative research in lung cancer prevention and clinical and translational medicine worldwide. Eleven young physicians and scientists received awards in 2016.

The IASLC Fellowships and Young Investigator Awards are for one year. The IASLC Asia Pacific Lung Cancer Conference Fellowship enables a researcher from that region to come to the U.S. to conduct a one-year research project. The IASLC also partners with like-minded organizations for the following research awards: the two-year Bonnie J. Addario Lung Cancer Foundation/IASLC Fellowship, the two-year Lung Cancer Foundation of America/IASLC/Lori Monroe Scholarship for Lung Cancer Research and the two-year IASLC/Prevent Cancer Foundation/Richard C. Deveraux Fellowship.

Selected from a pool of global applicants, researchers are evaluated by an international scientific panel for their merit, innovation and potential impact on the future management and treatment of lung cancer.

**IASLC Fellowship**

Luiz Henrique Araujo, PhD  
Brazilian National Cancer Institute, Rio de Janeiro, Brazil

Puey Ling Chia, MD  
Austin Health, Melbourne, Australia

Siddhartha Devarakonda, MD  
Washington University School of Medicine, St. Louis, Missouri, USA

Nicolas Reynoird, PhD  
Grenoble-Alpes University, Grenoble, France

**IASLC Young Investigator**

Esra Akbay, PhD  
Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Julie George, PhD  
University of Cologne, Cologne, Germany

**IASLC Asia Pacific Lung Cancer Conference Fellowship**

Apichat Tantraworasin, MD, PhD  
Icahn School of Medicine at Mount Sinai, New York, New York, USA
2016 LECTURESHP AWARDS

The IASLC recognized six investigators in 2016 with Lectureship Awards for their high-ranking World Conference on Lung Cancer abstracts in key areas of lung cancer research. These awards are named after IASLC members who have been leaders in the areas of pathology, surgery, small cell lung cancer, medical oncology and staging.

**Adi Gazdar Lectureship Award for Translational Research**

**RECIPIENT: JONATHAN RIESS, MD, MS**
University of California Davis Cancer Center, Davis, California, USA
Abstract: “Comprehensive Genomic Profiling and PDX Modeling of EGFR Exon 20 Insertions: Evidence for Osimertinib Based Dual EGFR Blockade”

**Robert Ginsberg Lectureship Award for Surgery**

**RECIPIENT: AKI KOBAYASHI, MSc, MD**
Mie University Graduate School of Medicine, Mie, Japan
Abstract: “Survival Outcomes in Sublobar Resection for Clinical T1N0M0 Non-Small Cell Lung Cancer: Wedge Resection or Segmentectomy”

**Heine Hansen Lectureship Award for Small Cell Lung Cancer**

**RECIPIENT: MARIANNA CHRISTODOULOU, MBChB, MRes**
The Christie NHS Foundation Trust, Manchester, United Kingdom
Abstract: “Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily versus Twice-Daily RadioTherapy (CONVERT) Trial”

**Dan Idhe Lectureship Award for Medical Oncology**

**RECIPIENT: KRISTA WINK, MD**
Maastro Clinic, Maastricht, Netherlands
Abstract: “Metformin Use During Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)”

**Clifton Mountain Lectureship Award for Staging**

**RECIPIENT: HAO-RAN ZHAI, MMED**
Guangdong Lung Cancer Institute, Guangdong General Hospital, Southern Medical University, Guangzhou, China
Abstract: “Evolutionary Trajectories of Molecular Progression in Different Subtypes of Primary Lung Adenocarcinomas”

**Tsuguo Naruke Lectureship Award for Surgery**

**RECIPIENT: RYUICHI WASEDA, MD, PhD**
Fukuoka University, Fukuoka, Japan
Abstract: “Anatomical Pulmonary Segmentectomy and Sub-Segmentectomy for Lung Cancer Using the Novel Fluorescence Technique with Vitamin B2”
IASLC ADVOCACY AWARDS

The IASLC Advocacy Awards are designed to increase connections between the IASLC, patient advocates and advocacy organizations throughout the world. The award is open to nonprofit organizations as well as individuals. All of the 2016 recipients – four of whom are lung cancer survivors – emphasize the need for advocates to be engaged in lung cancer research, treatment options and awareness and education efforts. They are passionate about making their voices heard through involvement with advisory boards, research panels, public awareness campaigns and government lobbying efforts.

Elizabeth Dessureault*
Lung cancer survivor/patient advocate
Ottawa, Canada

Kazuo Hasegawa
Lung cancer survivor/patient advocate
Yokohama, Japan

Lillian Leigh
Lung cancer survivor/patient advocate
Sydney, Australia

Ide Mills**
Lung cancer survivor/patient advocate
Maplewood, New Jersey, USA

Ewelina Szmytke
Patient advocate/board member, Lung Cancer Europe and Association for the Fight Against Lung Cancer
Banino, Poland

* Sadly, Elizabeth “Lizzie” Dessureault lost her courageous nearly two-year battle with lung cancer in February 2017. She is survived by her husband and young son.

** A lung cancer survivor of more than six years, Ide succumbed to the disease in April 2017. She is survived by her husband, son and daughter.
DEVELOPING NATION SCHOLARSHIP AWARDS

As recipients of the 2016 Developing Nation Scholarship Awards, 20 researchers from eight different countries received support to attend the IASLC 17th World Conference on Lung Cancer in Vienna, Austria. Each award recipient submitted an abstract that was chosen for presentation at the conference and worked on the research with a senior author who is an IASLC member. Developing nations are defined by the IASLC membership guidelines, which corresponds to the World Bank list of countries.

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>INSTITUTION</th>
<th>RECIPIENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brazil</td>
<td>National Cancer Institute of Brazil, Rio de Janeiro</td>
<td>Tatiane Montella</td>
</tr>
<tr>
<td>Brazil</td>
<td>University of Sao Paulo, Sao Paulo</td>
<td>Isis Nascimento</td>
</tr>
<tr>
<td>Brazil</td>
<td>National Cancer Institute-Ministry of Health, Rio de Janeiro</td>
<td>Ana Paula Teixeira</td>
</tr>
<tr>
<td>China</td>
<td>Shanghai Pulmonary Hospital, Shanghai</td>
<td>Weijing Cai</td>
</tr>
<tr>
<td>China</td>
<td>Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangzhou</td>
<td>Zhong-Yi Dong</td>
</tr>
<tr>
<td>China</td>
<td>Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai</td>
<td>Shengxiang Ren</td>
</tr>
<tr>
<td>China</td>
<td>Zhongshan Hospital Fudan University, Shanghai</td>
<td>Dawei Yang</td>
</tr>
<tr>
<td>China</td>
<td>West China Hospital, Sichuan University, Chengdu</td>
<td>Shuang Zhao</td>
</tr>
<tr>
<td>China</td>
<td>Fudan University Shanghai Cancer Center, Shanghai</td>
<td>Yue Zhao</td>
</tr>
<tr>
<td>Egypt</td>
<td>Ain Shams University, Cairo</td>
<td>Ahmed Salem</td>
</tr>
<tr>
<td>India</td>
<td>ICFAI University, West Tripura</td>
<td>Mani Bhargava</td>
</tr>
<tr>
<td>India</td>
<td>Tata Memorial Centre, Mumbai</td>
<td>Arun Chandrasekharan</td>
</tr>
<tr>
<td>India</td>
<td>Tata Memorial Centre, Mumbai</td>
<td>Alok Goel</td>
</tr>
<tr>
<td>India</td>
<td>GMERS Medical College, Ahmedabad</td>
<td>Guarav Kumar</td>
</tr>
<tr>
<td>India</td>
<td>Jamia Hamdard University, New Delhi</td>
<td>Ayaz Shahid</td>
</tr>
<tr>
<td>India</td>
<td>Postgraduate Institute of Medical Education and Research, Chandigarh</td>
<td>Navneet Singh</td>
</tr>
<tr>
<td>Malaysia</td>
<td>International Medical University, Kuala Lumpur</td>
<td>Chandrashekhar Sreeramreddy</td>
</tr>
<tr>
<td>Mexico</td>
<td>Instituto Nacional de Cancerologia, Mexico City</td>
<td>Denisse Lee-Cervantes</td>
</tr>
<tr>
<td>Russia</td>
<td>First Pavlov State Medical University of St. Petersburg, St. Petersburg</td>
<td>Andrey Akopov</td>
</tr>
<tr>
<td>Ukraine</td>
<td>Taras Shevchenko National University of Kyiv, Kyiv</td>
<td>Viktoria Nikulina</td>
</tr>
</tbody>
</table>
YOUNG INVESTIGATOR SCHOLARSHIP AWARDS

As recipients of the 2016 Young Investigator Scholarship Awards, 10 researchers from 10 different countries received support to attend the IASLC 17th World Conference on Lung Cancer in Vienna, Austria. Each award recipient submitted an abstract that was chosen for presentation at the conference and completed the research with a senior author who is an IASLC member. Young investigators are defined as researchers 35 years and younger.

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>INSTITUTION</th>
<th>RECIPIENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>Asbestos Diseases Research Institute, New South Wales</td>
<td>Kadir Sarun</td>
</tr>
<tr>
<td>Belgium</td>
<td>University of Antwerp, Antwerp</td>
<td>Elly Marcq</td>
</tr>
<tr>
<td>Canada</td>
<td>British Columbia Cancer Research Centre, Vancouver, British Columbia</td>
<td>Daiana Becker-Santos</td>
</tr>
<tr>
<td>China</td>
<td>Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou</td>
<td>Hao-ran Zhai</td>
</tr>
<tr>
<td>France</td>
<td>Cancer Research Center of Lyon, Lyon</td>
<td>Sandra Ortiz-Cuaran</td>
</tr>
<tr>
<td>Italy</td>
<td>University Hospital of Pisa, Pisa</td>
<td>Sara Ricciardi</td>
</tr>
<tr>
<td>Japan</td>
<td>Graduate School of Medicine, University of Tokyo, Tokyo</td>
<td>Takahiro Karasaki</td>
</tr>
<tr>
<td>Netherlands</td>
<td>Maastro Clinic, Maastricht</td>
<td>Krista Wink</td>
</tr>
<tr>
<td>South Korea</td>
<td>ASAN Medical Center, Seoul</td>
<td>Ji An Hwang</td>
</tr>
<tr>
<td>USA</td>
<td>University of North Carolina Hospitals, Chapel Hill, North Carolina</td>
<td>Kyle Wang</td>
</tr>
</tbody>
</table>

MENTORSHIP AWARDS

International Mentorship Program Fosters Worldwide Exchange of Expertise

The IASLC International Mentorship Program was established to provide professional development and education for early-career physicians who are studying thoracic malignancies.

“The idea is to bring young lung cancer investigators, particularly from developing countries, to a mentored program at the World Conference on Lung Cancer and let them spend time after the conference at the assigned mentor’s host institution,” says Fred R. Hirsch, MD, PhD, IASLC CEO.

The program was well received in 2016, with more than 40 applicants from all over the world. Candidates who apply to the Mentorship Program must submit an abstract or presentation at the World Conference on Lung Cancer (WCLC) and provide a personal statement on their goals and how the award will help them. The IASLC Fellowship Committee reviewed applications and selected 32 early-career researchers from 15 different countries. The awardees met daily with their assigned mentors during the WCLC to discuss relevant presentations and scientific achievements. The week following the conference, the mentees worked with their mentors at various cancer institutions throughout Europe and in Israel.

The IASLC is grateful to members who agree to be mentors. Robert Pirker, MD, Medical University of Vienna, Austria, says he volunteered to be a mentor because he wants to promote the global exchange of expertise. “I also want to meet young doctors who will become leading lung cancer experts in the future,” he adds.
# International Mentorship Program Awards

<table>
<thead>
<tr>
<th>Recipient</th>
<th>Country</th>
<th>Mentor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sandhya C. Acharya</td>
<td>Nepal</td>
<td>Christoph Zielinski, Austria</td>
</tr>
<tr>
<td>Ihsan Alloubi</td>
<td>Morocco</td>
<td>Eric Lim, United Kingdom</td>
</tr>
<tr>
<td>Marisol Arroyo Hernandez</td>
<td>Mexico</td>
<td>Fabrice Barlesi, France</td>
</tr>
<tr>
<td>Silvia Josefina Ayala Leon</td>
<td>Paraguay</td>
<td>Jan van Meerbeeck, Belgium</td>
</tr>
<tr>
<td>Chanchai Charompongsuntorn</td>
<td>Thailand</td>
<td>Rafael Rosell, Spain</td>
</tr>
<tr>
<td>Fabio Chaves</td>
<td>Portugal</td>
<td>Lucio Crino, Italy</td>
</tr>
<tr>
<td>Kezhong Chen</td>
<td>China</td>
<td>Mark Krasnik, Denmark</td>
</tr>
<tr>
<td>May Myat Cho</td>
<td>Thailand</td>
<td>Robert Pirker, Austria</td>
</tr>
<tr>
<td>Paola de la Iglesia</td>
<td>Argentina</td>
<td>Nir Peled, Israel</td>
</tr>
<tr>
<td>Carolina Gabay</td>
<td>Argentina</td>
<td>Giorgio Scaglotti, Italy</td>
</tr>
<tr>
<td>Shaodong Hong</td>
<td>China</td>
<td>Paul Baas, Netherlands</td>
</tr>
<tr>
<td>Omer Giray Intepe</td>
<td>Turkey</td>
<td>Paul van Schil, Belgium</td>
</tr>
<tr>
<td>Deepali Jain</td>
<td>India</td>
<td>Lukas Bubendorf, Switzerland</td>
</tr>
<tr>
<td>Ashish Jakhetiya</td>
<td>India</td>
<td>Walter Weder, Switzerland</td>
</tr>
<tr>
<td>Miica Kontic</td>
<td>Serbia</td>
<td>Nicolas Girard, France</td>
</tr>
<tr>
<td>Tomi Kovacevic</td>
<td>Serbia</td>
<td>Johan Vansteenkiste, Belgium</td>
</tr>
<tr>
<td>Vinaya Kumar, Jr.</td>
<td>India</td>
<td>Wilfried Eberhardt, Germany</td>
</tr>
<tr>
<td>Delfin Lovelina Francis</td>
<td>India</td>
<td>Odd Terje Brustugun, Norway</td>
</tr>
<tr>
<td>Rosa Luz Luna Palencia</td>
<td>Mexico</td>
<td>Jacek Jassem, Poland</td>
</tr>
<tr>
<td>Jose Nicolas Minatta</td>
<td>Argentina</td>
<td>James Spicer, United Kingdom</td>
</tr>
<tr>
<td>Xiaomin Niu</td>
<td>China</td>
<td>Fiona Blackhall, United Kingdom</td>
</tr>
<tr>
<td>Pierpaolo Pastina</td>
<td>Italy</td>
<td>Suresh Senan, Netherlands</td>
</tr>
<tr>
<td>Sandra Perdomo</td>
<td>France</td>
<td>Caroline Dive, United Kingdom</td>
</tr>
<tr>
<td>Fawaz Pullishery</td>
<td>India</td>
<td>Martin Filipits, Austria</td>
</tr>
<tr>
<td>Chuxia Su</td>
<td>China</td>
<td>Mary O’Brien, United Kingdom</td>
</tr>
<tr>
<td>Adam Szpechcinski</td>
<td>Poland</td>
<td>Celine Mascaux, France</td>
</tr>
<tr>
<td>Vikas Talreja</td>
<td>India</td>
<td>Luis Paz-Áres, Spain</td>
</tr>
<tr>
<td>Satheesh Thangappa</td>
<td>India</td>
<td>Christian Rolfo, Belgium</td>
</tr>
<tr>
<td>Fengying Wu</td>
<td>China</td>
<td>Simon Ekman, Sweden</td>
</tr>
<tr>
<td>Daniela Xhemalaj</td>
<td>Albania</td>
<td>Ales Ryska, Czech Republic</td>
</tr>
<tr>
<td>Shi Xiaohua</td>
<td>China</td>
<td>Johan Botling, Sweden</td>
</tr>
<tr>
<td>Yi-Chen Zhang</td>
<td>China</td>
<td>Benjamin Besse, France</td>
</tr>
</tbody>
</table>
The IASLC would like to thank its sponsors for their generous support.
The IASLC Foundation supports the International Association for the Study of Lung Cancer (IASLC) by providing fellowships to researchers worldwide to aid their work in finding new ways to conquer lung cancer and other thoracic malignancies.

The IASLC Foundation has been established to create a new avenue of support to foster additional groundbreaking and collaborative research worldwide.

The mission of the IASLC Foundation is to support the IASLC in order to:

› embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies;

› provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large and to the public;

› use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.

The Foundation supports researchers, rewards scientific excellence and encourages innovative research in lung cancer prevention and translational medicine around the world.

In 2015, the Foundation had a strong start with a generous donation from Dr. Adi F. Gazdar. Relying on this substantial gift as seed money allowed the IASLC Foundation to start funding 2016 fellowships.

The Foundation’s Matching Gift Challenge, sponsored by the IASLC Board of Directors, encouraged giving from those already involved with the organization as well as from the general public. Additionally, the Mozart’s Requiem Concert held at the IASLC 17th World Conference on Lung Cancer increased awareness and support of the IASLC Foundation.

Through the efforts of the Fellowship Matching Gift Challenge and the Mozart’s Requiem Concert, the Annual Fund donor base grew significantly in 2016.

For more information on the Foundation, to view the donor benefit levels, or to donate, please visit www.iaslc.org/foundation.
IASLC Foundation Board

David Carbone, President
Fred R. Hirsch, CEO and Secretary
David Gandara, Treasurer
Giorgio Scagliotti, President-Elect
Tony Mok, Past President

Marc Braunstein, Member
Lauren Fisher, Member
Ivar Samren, Member
Kathy Weber, Member

2016 ANNUAL FUND DONORS

THE 2016 PRESIDENT'S CIRCLE

Platinum Level - $50,000 and above
Adi F. Gazdar

Gold Level - $10,000 - $49,999
Lauren Fisher and John's Legacy Fund (In loving memory of John Fredrick Fisher)

Silver Level - $5,000 - $9,999
Paul A. Bunn, Jr.
Mary Ellen Honeyfield
Kathy Weber and the Chris Draft Family Foundation

Bronze Level - $1,000 - $4,999
Michael J. Boyer
Marc Braunstein
David Paul Carbone
Yoon-La Choi
David R. Gandara
Roy S. Herbst
Fred R. and Pia Hirsch
Norihiko Ikeda
Pasi Janne
Keith M. Kerr
Edward Kim
Tony Shu Kam Mok
Lisa Moran
Yuichiro Ohe
Ray U. Osarogiagbon
Solang Peters
Pikes Peak Browns Backers
Giorgio V. Scagliotti
Heather Wakelee
Glen Weiss (In memory of Yosef Moshe)

2016 ANNUAL FUND MEMBERS

Sarah Aiosa
Esra Akbay (In memory of my grandfather who died of lung cancer)
Maria Amelia Brilhante Almeida
Anonymous
Douglas Arenberg
John H.M. Austin
David Ball
Pamela Bartlett
Bethanie Berube (In honor of survivor Valerie Legare)
Peter Berzinec
Wendy Binyon
Haim Biran
Susan Blackwell
Elisabeth Brambilla
Vera Luiza Capelozzi
Sandro Cavallero
Cynthia Chan
Hung Kei Chan
Virginia Chandler
Rattiya Cheewakriangkrai
Hua Cheng
Rony P. Colanzi
Marianne J. Davies
Emily Larie Davis
Claude Deschamps
Martin Edelman
Yener S. Erozan
Takashi Eto
Wilbur A. Franklin
Etsuo Fujita Shirish Gadgeel
Laurie E. Gaspar
Kim R. Geisinger
Jake Gjoraas (In memory of Renee Hertog)
John R. Goffin
Peter Goldstraw
Hari Kishan Gonuguntla
Bernardo Goulart
Ulrike Gruber-Moesenbacher
Teresa Haga-Golaszewski (For anyone with small cell lung cancer)
Xiangkun Han
Kim Harrow
Teodor Horvath
Mark Huberman
Klaus L. Irion
Helgi J. Isaksson
James R. Jett
Michael Jones
Gregory Kalemkerian
2016 ANNUAL FUND MEMBERS, CONTINUED

Tatsuhiko Kashii
Hyun Koo Kim
Ebenezer Kio
Takumi Kishimoto
Koizumi Kiyoji
Julie Konzak (In support of Ann Molter, who is courageously fighting it! Love you Ann! And in memory of my mom)
Paris A. Kosmidis
Mark G. Kris
Marc A.E. Lambrechts
David Landau
Michael Lanuti
Dong Soo Lee
Tianhong Li
Hongxu Liu
Aijaz Lone
James D. Luketich
Katsuaki Maehara
Danielle Calheiros Maia
Norikazu Matsuo
Fred Messina
Mari Mino-Kenudson
Tetsuya Mitsudomi
Andrea Mohn-Staudner
Donato Monaco (In memory of Anna Lino from pre-K, 1st and 4th grade families at St. Paul School)
Takashi Nakano
James Newman (In memory of Anna Lino from the St. Paul School soccer team)
Akihiro Nishiyama
Masayuki Noguchi
Kenneth J. O’Byrne
Marissa Edith Page (In memory of my daddy, Robert Oscar Grondin)
The Parulski Family (In memory of Anna Lino)
Joanna Peluso
Branislav Perin
Robert Pirker
Erhard Prantz
Joerg Rathmann
Kristin Richeimer
Jaime Rodriguez-Canales
Kenneth E. Rosenzweig
Ikuko Sakai
Ivar Samren
Miyako Satouchi
Vasil Savov
Arnold M. Schwartz
Nevena M. Secen
Wendy Shaver
Anna Elizabeth Sienko
John Skadow
Margaret Speas (Happy Christmas to Rita and Richard Johnson)
Matthew Steliga
Emily Stone

THE LEGACY OF JOHN FISHER

In 2015, John Fisher rapidly became ill and passed away from mesothelioma, a thoracic cancer. His wife, Lauren, established a fund in his memory, John’s Legacy, honoring his life’s focus on making a difference in the lives of others. Two-thirds of the proceeds raised by John’s Legacy will go to the IASLC Foundation, specifically to aid in efforts based out of Colorado.